Effect of Combined Polyphenol on the Disease Course in Children Diagnosed with Influenza
Pharmaceutics, cilt.18, sa.7, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 7
- Basım Tarihi: 2026
- Doi Numarası: 10.3390/pharmaceutics18070858
- Dergi Adı: Pharmaceutics
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO)
- Anahtar Kelimeler: influenza, child, polyphenol, antiviral therapy
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: This multicenter retrospective real-world data study aimed to evaluate whether the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with symptom duration and severity, time to fever resolution, and functional recovery in children diagnosed with influenza. Materials and Methods: This was a five-center, multicenter, retrospective, comparative real-world data analysis. A total of 128 patients aged 4–10 years with a clinical diagnosis of influenza were classified into a control group receiving antiviral therapy alone (n = 64) and a combined polyphenol group receiving, in addition to antiviral therapy, a preparation containing polyphenol, vitamin D3, vitamin C, and zinc (n = 64). Clinical data were obtained from electronic patient records and parent-reported information. Symptom severity (0–3 ordinal score), recovery time, and functional outcomes were assessed on Days 0, 3, 5, and 7. Continuous variables were compared using the independent-samples t test, categorical variables using the chi-square or Fisher exact test, and changes over time using a repeated-measures general linear model. Statistical significance was accepted as a two-sided p value of <0.05. Results: In this study including 128 pediatric patients, there were no significant differences between the combined polyphenol and control groups in demographic or baseline clinical characteristics (p > 0.05). During follow-up, all symptom scores improved more rapidly and markedly in the combined polyphenol group than in the control group. By Day 3, significant differences were observed between groups in fever, cough, rhinorrhea, sore throat, fatigue, general condition, and physical activity scores (p < 0.001 for all parameters). By Day 5, almost complete resolution of symptoms (score 0) was observed in the combined polyphenol group, whereas symptoms persisted to a substantial extent in the control group (p < 0.001). The time to fever resolution was significantly shorter in the combined polyphenol group (1.84 ± 0.72 days vs. 4.5 ± 1.36 days; p < 0.001). Similarly, time to return to school (3.21 ± 0.9 days vs. 5.8 ± 1.91 days; p < 0.001) and time for parents to return to work were significantly shorter in the combined polyphenol group (p < 0.001). The need for additional healthcare visits and antipyretic use was markedly lower in the combined polyphenol group (Day 3: 20.3% vs. 53.1%; Day 5: 0% vs. 15.6%; p < 0.001 for both comparisons). Repeated-measures analyses showed a significant time-by-group interaction, indicating that the reduction in symptom scores occurred more rapidly and prominently in the combined polyphenol group (p < 0.001). Treatment was generally well tolerated in the combined polyphenol group; no serious adverse events were reported, and parent-reported tolerability was high (9.39 ± 0.7). Conclusions: This multicenter retrospective real-world data study suggests that the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with shorter symptom duration, lower symptom severity scores, and faster functional recovery in children diagnosed with influenza. These findings suggest that this combination may represent a promising and well-tolerated adjunctive approach in the management of pediatric influenza.